PW Medtech Group Dirección

Dirección controles de criterios 4/4

El CEO de PW Medtech Group's es Yue'e Zhang , nombrado en Mar 2019, tiene una permanencia de 5.08 años. compensación anual total es CN¥1.01M, compuesta por 100% salario y 0% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.003% de las acciones de la empresa, por valor de HK$46.95K. La antigüedad media del equipo directivo y de la junta directiva es de 4.3 años y 10.7 años, respectivamente.

Información clave

Yue'e Zhang

Chief Executive Officer (CEO)

CN¥1.0m

Compensación total

Porcentaje del salario del CEO	100.0%
Permanencia del CEO	5.2yrs
Participación del CEO	0.003%
Permanencia media de la dirección	4.3yrs
Promedio de permanencia en la Junta Directiva	10.8yrs

Actualizaciones recientes de la dirección

Recent updates

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Mar 14

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

Nov 23

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

Feb 18

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Nov 22

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Yue'e Zhang en comparación con los beneficios de PW Medtech Group?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	n/a	n/a	CN¥153m
Sep 30 2023	n/a	n/a	CN¥135m
Jun 30 2023	n/a	n/a	CN¥116m
Mar 31 2023	n/a	n/a	CN¥111m
Dec 31 2022	CN¥1m	CN¥1m	CN¥106m
Sep 30 2022	n/a	n/a	CN¥72m
Jun 30 2022	n/a	n/a	CN¥39m
Mar 31 2022	n/a	n/a	CN¥389m
Dec 31 2021	CN¥1m	CN¥1m	CN¥739m
Sep 30 2021	n/a	n/a	CN¥995m
Jun 30 2021	n/a	n/a	CN¥1b
Mar 31 2021	n/a	n/a	CN¥942m
Dec 31 2020	CN¥1m	CN¥1m	CN¥632m
Sep 30 2020	n/a	n/a	CN¥398m
Jun 30 2020	n/a	n/a	CN¥163m
Mar 31 2020	n/a	n/a	CN¥123m
Dec 31 2019	CN¥1m	CN¥1m	CN¥82m
Jun 30 2019	n/a	n/a	CN¥136m
Mar 31 2019	n/a	n/a	CN¥126m
Dec 31 2018	CN¥995k	CN¥995k	CN¥115m
Jun 30 2018	n/a	n/a	CN¥27m
Mar 31 2018	n/a	n/a	CN¥16m
Dec 31 2017	CN¥1m	CN¥1m	CN¥5m

Compensación vs. Mercado: La compensación total de Yue'e($USD139.58K) está por debajo de la media de empresas de tamaño similar en el mercado Hong Kong ($USD339.94K).

Compensación vs. Ingresos: La compensación de Yue'e ha sido consistente con los resultados de la empresa en el último año.

CEO

Yue'e Zhang (60 yo)

5.2yrs

Permanencia

CN¥1,011,000

Compensación

Ms. Yue'e Zhang has been Chief Executive Officer at PW Medtech Group Ltd. since March 31, 2019. Ms. Zhang serves as a General Manager, Senior Engineer and Executive Director of WP Medical Technologies, Inc...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Yue'e Zhang	Executive Chairman & CEO	5.2yrs	CN¥1.01m	0.0032% CN¥ 47.4k
Tian Tian	Financial Director	4.3yrs	sin datos	sin datos
Ka Man So	Company Secretary	1.8yrs	sin datos	sin datos

4.3yrs

Permanencia media

49yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 1358 se considera experimentado (4.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Yue'e Zhang	Executive Chairman & CEO	13yrs	CN¥1.01m	0.0032% CN¥ 47.4k
Xiaogang Wang	Independent Non-Executive Director	10.6yrs	CN¥172.00k	sin datos
Geng Chen	Independent Non-Executive Director	10.6yrs	CN¥172.00k	0.041% CN¥ 605.1k
Liwei Jiang	Non-Executive Director	10.9yrs	CN¥300.00k	0.17% CN¥ 2.5m
Junshan Lin	Non-Executive Director	10.9yrs	CN¥300.00k	0.11% CN¥ 1.6m
Fengli Wang	Independent Non-Executive Director	2.8yrs	CN¥172.00k	sin datos

10.8yrs

Permanencia media

58yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de 1358 son experimentados ( 10.7 años antigüedad media).

PW Medtech Group Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Recent updates

PW Medtech Group Limited, Annual General Meeting, Jun 14, 2024

Full year 2023 earnings released: EPS: CN¥0.098 (vs CN¥0.068 in FY 2022)

PW Medtech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

There's Reason For Concern Over PW Medtech Group Limited's (HKG:1358) Price

Upcoming dividend of HK$0.049 per share at 11% yield

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Announces Interim (Semi-Annual) Dividend for the Six Months Ended 30 June 2023, Payable on October 24, 2023

PW Medtech Group Limited Provides Unaudited Consolidated Earnings Guidance for the Six Months Ended 30 June 2023

PW Medtech Group Limited to Report First Half, 2023 Results on Aug 31, 2023

New minor risk - Market cap size

Full year 2022 earnings released: EPS: CN¥0.068 (vs CN¥0.47 in FY 2021)

We Think PW Medtech Group (HKG:1358) Can Manage Its Debt With Ease

First half 2022 earnings released: EPS: CN¥0.039 (vs CN¥0.48 in 1H 2021)

PW Medtech Group Limited Announces Executive Changes

PW Medtech Group Limited Provides Consolidated Earnings Guidance for the Six Months Ended June 30, 2022

PW Medtech Group Limited to Report First Half, 2022 Results on Aug 31, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited, Annual General Meeting, Jun 08, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

PW Medtech Group Limited (SEHK:1358) agreed to acquire 51.5% stake in Beijing Ruijian High-Tech Biological Technology Co., Ltd from a group of shareholders for CNY 412 million.

First half 2021 earnings released: EPS CN¥0.48 (vs CN¥0.09 in 1H 2020)

Investor sentiment improved over the past week

Independent Non-Executive Director Xingdong Zhang has left the company

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

Full year 2020 earnings released: EPS CN¥0.40 (vs CN¥0.052 in FY 2019)

PW Medtech Group Limited to Report Fiscal Year 2020 Results on Mar 30, 2021

How Much Have PW Medtech Group (HKG:1358) Shareholders Earned On Their Investment Over The Last Five Years?

New 90-day low: HK$0.52

Should You Rely On PW Medtech Group's (HKG:1358) Earnings Growth?

New 90-day high: HK$2.31

CITIC Capital Holdings Limited completed the acquisition of 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358).

Here's Why PW Medtech Group (HKG:1358) Can Manage Its Debt Responsibly

Should You Be Adding PW Medtech Group (HKG:1358) To Your Watchlist Today?

New 90-day high: HK$2.29

What You Need To Know About PW Medtech Group Limited's (HKG:1358) Investor Composition

Market bids up stock over the past week

CITIC Capital Holdings Limited entered into an agreement to acquire 2.4% stake in China Biologic Products Holdings, Inc. (NasdaqGS:CBPO) from PW Medtech Group Limited (SEHK:1358) for approximately $110 million.

New 90-day high: HK$1.76

First half earnings released

PW Medtech Group Limited to Report First Half, 2020 Results on Aug 27, 2020

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad